Elutia (ELUT) Q1 2026 earnings summary

Executive summary

• Focus sharpened on drug-eluting biomatrix solutions for breast reconstruction, with NXT-41 and NXT-41x as lead pipeline products; advanced FDA review and productive interactions increase confidence in regulatory timelines.

• Automated manufacturing platform for NXT-41x is fully operational, supporting targeted gross margins above 80% at scale.

• Strategic divestitures underway, including SimpliDerm and inbound interest for the Cardiovascular product line; CIED and Orthobiologics businesses sold for up to $88M and $14.6M plus earn-outs.

• Strong balance sheet with $36.5M in cash and escrowed proceeds as of March 31, 2026.

• Commercial team engagement and market research confirm a $1.5B U.S. breast reconstruction market with high unmet need and concentrated opportunity.

Financial highlights

• Q1 2026 net sales were $3.1M, up 6% year-over-year from $3.0M, driven by cardiovascular segment gains.

• SimpliDerm revenue was $2.1M (down from $2.6M YoY); cardiovascular revenue was $1.0M (up from $0.3M YoY).

• GAAP gross margin improved to 57.9% from 46.8% YoY; adjusted gross margin (excl. intangible amortization) rose to 66.5% from 55.9%.

• Net loss from continuing operations was $7.9M, compared to $1.9M in Q1 2025, mainly due to a $6.7M swing in other expense (income), including non-cash warrant revaluation.

• Adjusted EBITDA loss was $4.4M (vs. $2.8M YoY); operating expenses were $8.2M, flat YoY, with increased R&D and sales/marketing spend.

Outlook and guidance

• NXT-41 FDA clearance expected Q4 2026; NXT-41x submission planned for Q4 2026 and clearance anticipated H1 2027.

• Commercialization and soft launch of NXT-41x targeted for H2 2027 into a $1.5B U.S. market.

• Strategic transactions (SimpliDerm and cardiovascular) expected to further strengthen balance sheet.

• Expectation of continued operating losses and negative cash flows as development of NXT-41 and NXT-41x advances; cash expected to fund operations for at least one year.